Literature DB >> 6259457

Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases.

P Iwangoff, R Armbruster, A Enz, W Meier-Ruge.   

Abstract

The activities of glycolytic enzymes were determined in human autoptic temporal lobes from patients with different forms of dementia. For some enzymes (hexokinase, phosphofructokinase and phosphoglycerate mutase) the effect seen in dementia can be regarded as an intensification of the normal ageing affect. For other enzymes (aldolase, phosphoglucose isomerase, triosephosphate isomerase and lactate dehydrogenase) no changes in enzyme activities corresponding to those found in dementia are observed in the normal ageing process. These effects are most pronounced in the non-vascular Alzheimer cases. With the exception of triosephosphate isomerase and lactate dehydrogenase, enzyme activity is also reduced in bronchopneumonia. The effects of dementia and bronchopneumonia on the activities of glycolytic enzymes in human autoptic brain tissue are often difficult to distinguish.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6259457     DOI: 10.1016/0047-6374(80)90120-7

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  30 in total

1.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

Review 2.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

Review 3.  Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Authors:  Ramesh Kandimalla; Vani Thirumala; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-08-25       Impact factor: 5.187

4.  Long-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction.

Authors:  Zhuo Fu; Jing Wu; Tanseli Nesil; Ming D Li; Kevin W Aylor; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-29       Impact factor: 4.310

Review 5.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

Review 6.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

7.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

Review 8.  Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

Authors:  Suzanne M de la Monte
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-28       Impact factor: 4.600

9.  Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.

Authors:  Rukhsana Sultana; Marzia Perluigi; Shelley F Newman; William M Pierce; Chiara Cini; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2010-03       Impact factor: 8.401

Review 10.  Linking insulin with Alzheimer's disease: emergence as type III diabetes.

Authors:  Sara Ahmed; Zahra Mahmood; Saadia Zahid
Journal:  Neurol Sci       Date:  2015-08-07       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.